Table 2.
Characteristics of 83 participants with type 2 diabetes by TNFR1 and TNFR2 percentiles.
| Strata of TNFR1 (percentiles) | ||||
|---|---|---|---|---|
|
| ||||
| Clinical Characteristics | T1 (n=19) | T2 (n=43) | T3 (n=21) | p |
| Measured Markers | ||||
| TNFR1 (pg/mL) | 1055 (931-1120) | 1500 (1374-1653) | 2156 (2039-2564) | |
| TNFR2 (pg/mL) | 2214 (1937-2471) | 3284 (2935-3629) | 4756 (4135-5250) | <0.001 |
| TNFα (pg/mL)a | 4.6 (3.1-5.9) | 4.1 (2.7-5.1) | 4.1 (3.0-5.6) | 0.82 |
|
| ||||
| Other Characteristics | ||||
| Age (years)b | 42.9 ± 9.8 | 46.4 ± 9.9 | 49.1 ± 10.3 | 0.15 |
| Diabetes duration (years) | 13.0 (11.2-19.4) | 14.0 (11.1-20.5) | 15.0 (12.4-22.4) | 0.33 |
| Body mass index (kg/m2) | 31.4 (27.6-38.4) | 33.3 (29.8-40.0) | 36.1 (31.7-44.6) | 0.14 |
| A1c (%) | 9.4 (7.6-10.9) | 9.2 (7.5-11.5) | 9.2 (7.6-11.2) | 0.98 |
| Systolic blood pressure (mmHg) | 119 (107-125) | 124 (109-132) | 127 (117-141) | 0.10 |
| Diastolic blood pressure (mmHg) | 74 (70-84) | 76 (70-83) | 82 (72-87) | 0.24 |
| Mean arterial pressure (mmHg) | 89 (83-98) | 92 (85-97) | 96 (88-104) | 0.11 |
| Serum creatinine (mg/dL) | 0.61(0.5-0.67) | 0.67 (0.60-0.79) | 0.76 (0.68-0.97) | <0.001 |
| ACR (mg/g) | 18 (12-41) | 26 (10-88) | 97 (28-923) | 0.02 |
| mGFR (ml/min) | 150 (117-170) | 136 (107-188) | 115 (85-133) | 0.04 |
| mGFR (ml/min/1.73m2) | 136 (117-160) | 123 (94-161) | 102 (81-110) | 0.004 |
| Hypertension treatment (%)c | 26 | 47 | 57 | 0.14d |
| Losartan treatment assignment (%)e | 63 | 58 | 33 | 0.11d |
| Diabetes treatment (%) | 89 | 86 | 100 | 0.21d |
| Lipid lowering treatment (%) | 21 | 33 | 33 | 0.62d |
|
| ||||
| Strata of TNFR2 (percentiles) | ||||
|
| ||||
| Clinical Characteristics | T1 (n=21) | T2 (n=42) | T3 (n=20) | p |
|
| ||||
| Measured Markers | ||||
| TNFR1 (pg/mL) | 1093 (970-1159) | 1509 (1369-1854) | 2218 (1981-2585) | <0.001 |
| TNFR2 (pg/mL) | 2227 (2054-2496) | 3290 (2984-3590) | 4848 (4561-5390) | |
| TNFα (pg/mL)f | 4.6 (3.1-5.9) | 3.7 (2.9-4.7) | 5.0 (2.5-6.7) | 0.34 |
|
| ||||
| Other Characteristics | ||||
| Age (years)b | 45.3 ± 9.2 | 46.9 ± 10.5 | 48.0 ± 10.6 | 0.68 |
| Diabetes duration (years) | 12.9 (11.3-15.0) | 14.3 (11.7-20.9) | 15.3 (12.6-19.6) | 0.41 |
| Body mass index (kg/m2) | 31.4 (28.3-37.7) | 33.3 (29.8-39.2) | 38.6 (32.1-44.8) | 0.09 |
| A1c (%) | 9.1 (6.5-10.4) | 9.7 (8.3-11.5) | 8.8 (7.2-11.4) | 0.11 |
| Systolic blood pressure (mmHg) | 111 (107-125) | 124 (114-132) | 126 (117-141) | 0.046 |
| Diastolic blood pressure (mmHg) | 74 (70-83) | 77 (72-83) | 79 (70-87) | 0.56 |
| Mean arterial pressure (mmHg) | 89 (82-95) | 93 (87-98) | 94 (87-103) | 0.17 |
| Serum creatinine (mg/dL) | 0.65 (0.57-0.69) | 0.67 (0.60-0.74) | 0.8 (0.66-0.99) | 0.009 |
| ACR (mg/g) | 18 (12-45) | 27 (12-97) | 93 (20-978) | 0.03 |
| mGFR (ml/min) | 142 (126-167) | 134 (107-191) | 119 (102-141) | 0.14 |
| mGFR (ml/min/1.73m2) | 134 (117-158) | 122 (101-169) | 103 (84-121) | 0.05 |
| Hypertension treatment (%)g | 29 | 48 | 55 | 0.20d |
| Losartan treatment assignment (%)e | 67 | 50 | 45 | 0.33d |
| Diabetes treatment (%) | 81 | 95 | 90 | 0.20d |
| Lipid lowering treatment (%) | 24 | 36 | 25 | 0.53d |
T1, TNFR1 and TNFR2 <25th percentile; T2, TNFR1 and TNFR2 25th to 75th percentile; T3, TNFR1and TNFR2 >75th percentile.
TNFR1 values for the 25th percentile cut point=1205 pg/mL, and for the 75th percentile cut point=1960 pg/mL.
TNFR2 values for the 25th percentile cut point=2671 pg/mL, and for the 75th percentile cut point=4152 pg/mL.
Values are medians (25th and 75th centile).
n=74; 17; 37; 20.
Mean ± standard deviation.
T1=2 on ACE and 2 on ARB; T2=17 on ACE and 3 on ARB; T3=11 on ACE and 1 on ARB.
P values from Mantel-Haenszel χ2 test for general association.
Assigned to receive losartan during clinical trial.
n=74; 19; 36; 19.
T1=4 on ACE and 1 on ARB; T2=17 on ACE and 3 on ARB; T3=9 on ACE and 2 on ARB.
ACR, urinary albumin-to-creatinine ratio; A1c, hemoglobin A1c; mGFR, iothalamate glomerular filtration rate; TNFα, tumor necrosis factor α; TNFR, tumor necrosis factor receptor.